Table 3 Hazard ratios (HR) of all-cause mortality and having a major cardiac event, Survival analysis, N = 325 (stage IV and unknown stage of breast cancer and sarcoma excluded); and exploratory analysis of major cardiac events (MACE) after follow-up CT scan, N = 306 (patients with MACE prior to follow-up CT scan excluded)
Parameter | Model 1a (All-cause mortality) HR (95% CI) | Model 2b (MACE) HR (95% CI) | Model 3b,c (MACE) HR (95% CI) |
|---|---|---|---|
PMI at baseline [7.9 vs. 5.0] | 0.87 (0.60–1.26) | 0.60 (0.36–1.00) | N/A |
PMI at baseline, linear effect only | N/A | N/A | 0.84 (0.73–0.97) |
PMI, %-change between baseline and follow-up, linear effect only | N/A | N/A | 1.00 (0.99–1.01) |
Age at baseline [67 vs. 53] | 1.05 (0.72–1.52) | 2.15 (1.16–3.99) | N/A |
Stage | N/A | N/A | |
I or II | 1 (Ref.) | ||
III or IV | 1.52 (0.90–2.56) | ||
Unknown | 1.48 (0.59–3.71) | ||
Smoking history | N/A | N/A | |
Never | 1 (Ref.) | ||
Ever | 1.45 (0.94–2.23) | ||
Sex | |||
Female | 1 (Ref.) | ||
Male | 1.41 (0.82–2.44) | 0.94 (0.48–1.96) | |
Cancer Type | N/A | N/A | |
Breast | 0.54 (0.28–1.04) | ||
Lymphoma | 1 (Ref.) | ||
Sarcoma | 1.54 (0.83–2.88) | ||
Pre-treatment LVEF | N/A | N/A | |
> 55% | 1 (Ref.) | ||
< 55% | 3.12 (1.37–7.11) | ||